The GLP-1-Based Therapeutics Summit is the Ultimate Industry Forum for Developers of GLP-1-Based Therapeutics Across Different Indications
The GLP-1-Based Therapeutics Summit is a once-a-year event, uniting 60+ industry experts to help advance more specialized, durable, and efficacious GLP-1s while investigating commercial opportunities to crystallize pipeline strategy and indication expansion.
Grab your copy of the full agenda
Amidst the resounding success of Novo’s SELECT trial, the clinical trial landscape finds itself inundated with a surge of innovative GLP-1 treatments. Each passing week witnesses the unveiling of new multi-million-dollar investments, propelling GLP-1 players to the forefront of pharmaceutical revenue growth.
Key Highlights:
Unraveling Exciting Opportunities to Apply GLP-1 Receptor Agonists Across a Wide Range of Indications
Including cardiovascular, renal, obstructive sleep apnea, MASH, and neurodegenerative diseases with Eli Lily, D&D Pharmatech, and Altimmune
Optimizing the Efficacy of GLP-1-Based Therapeutics
Hear the newest innovations raising the benchmark for more successful weight loss with Diasome Pharmaceuticals and BioAge Labs
Developing a Robust Commercial Strategy
Differentiate your GLP-1 products from your competitors, to effectively target specific patient segments with Altimmune and Regor Therapeutics